The Discovery and Development of Liraglutide and Semaglutide.
Quick Facts
What This Study Found
Systematic optimization of fatty acid acylation transformed GLP-1 from a 1.5-minute half-life peptide into once-daily liraglutide (C16, 13h) and once-weekly semaglutide (C18 diacid, 165h).
Key Numbers
GLP-1 native: 1.5 min; liraglutide: C16, 13h half-life; semaglutide: C18 diacid, 165h half-life; 5.6x albumin affinity increase
How They Did This
Historical review of drug discovery and development at Novo Nordisk.
Why This Research Matters
Definitive account of how lipidation chemistry created the most commercially successful peptide drugs in history.
What This Study Doesn't Tell Us
Industry-authored review.
Trust & Context
- Original Title:
- The Discovery and Development of Liraglutide and Semaglutide.
- Published In:
- Frontiers in endocrinology, 10, 155 (2019)
- Authors:
- Knudsen, Lotte Bjerre, Lau, Jesper
- Database ID:
- RPEP-04284
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04284APA
Knudsen, Lotte Bjerre; Lau, Jesper. (2019). The Discovery and Development of Liraglutide and Semaglutide.. Frontiers in endocrinology, 10, 155. https://doi.org/10.3389/fendo.2019.00155
MLA
Knudsen, Lotte Bjerre, et al. "The Discovery and Development of Liraglutide and Semaglutide.." Frontiers in endocrinology, 2019. https://doi.org/10.3389/fendo.2019.00155
RethinkPeptides
RethinkPeptides Research Database. "The Discovery and Development of Liraglutide and Semaglutide..." RPEP-04284. Retrieved from https://rethinkpeptides.com/research/knudsen-2019-the-discovery-and-development
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.